GLP-1 receptor agonists for Alzheimer’s disease: Lessons from trials and translational challenges

Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review

Abstract Background Neurodegenerative disorders, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), present substantial global health challenges due to a lack of disease-modifying therapies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), traditionally used in type 2 diabetes management, have em...

Cross-sectional retrospective analysis assessing the role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa

GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program.

The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brai...

Genetic and molecular evidence linking CTSH to Alzheimer's disease pathophysiology

Lysosomal dysfunction contributes to Alzheimer's disease (AD) by impairing protein clearance and promoting neuroinflammation. Cathepsin H (CTSH), a lysosomal protease, recently emerged as a protective AD locus. We investigated how CTSH is regulated and how it influences early AD pathophysiology.

Dysregulated mRNA Translation in Alzheimer’s Disease: Mechanisms, Therapeutic Opportunities, and Challenges for Clinical Translation

: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and a growing public health concern. Its core pathological features include cerebral amyloid-β deposition and tau aggregation. mRNA translation is a tightly regulated process essential for gene expression and protein synthesis. It plays critical rol...

GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded beyond glycemic control to include cardiovascular and renal risk reduction, with recent approval for reducing major adverse cardiovascular events in individuals with obesity or overweight and established cardiovascular disease. Increasing attention has...